Fri 03 December 2021:
British regulators on Thursday approved GlaxoSmithKline drug sotrovimab to treat those at high risk of developing severe COVID-19 symptoms, with the manufacturer saying it “retains activity” against the new Omicron variant.
The monoclonal antibody “was found to be safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease,” said the Medicines and Healthcare products Regulatory Agency (MHRA).
Antibody treatments remain one of a handful of therapies that can blunt the worst effects of COVID-19, and they are the only option available to people with mild-to-moderate cases who aren’t yet in the hospital.
The drugs are laboratory-made versions of virus-fighting antibodies that the immune system uses to defend against infections.
_____________________________________________________________________________
FOLLOW INDEPENDENT PRESS:
TWITTER (CLICK HERE)
https://twitter.com/IpIndependent
FACEBOOK (CLICK HERE)
https://web.facebook.com/ipindependent
Think your friends would be interested? Share this story!
